Zobrazeno 1 - 10
of 42
pro vyhledávání: '"J A, Neidhart"'
Autor:
D G, Maloney, A J, Grillo-López, C A, White, D, Bodkin, R J, Schilder, J A, Neidhart, N, Janakiraman, K A, Foon, T M, Liles, B K, Dallaire, K, Wey, I, Royston, T, Davis, R, Levy
Publikováno v:
Blood. 90(6)
IDEC-C2B8 is a chimeric monoclonal antibody (MoAb) directed against the B-cell-specific antigen CD20 expressed on non-Hodgkin's lymphomas (NHL). The MoAb mediates complement and antibody-dependent cell-mediated cytotoxicity and has direct antiprolife
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e86adb8b5cae2018840b4d97f4a29a85
https://pubmed.ncbi.nlm.nih.gov/9310469
https://pubmed.ncbi.nlm.nih.gov/9310469
Autor:
J C, Yau, J A, Neidhart, P, Triozzi, S, Verma, J, Nemunaitis, D P, Quick, D G, Mayernik, D H, Oette, F A, Haynes, J, Holcenberg
Publikováno v:
American journal of hematology. 51(4)
This is a double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of granulocyte-macrophage colony-stimulating-factor (GM-CSF) after dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP). Fifty-six patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4679fe0ea7582eda98e8c1b63ae64660
https://pubmed.ncbi.nlm.nih.gov/8602629
https://pubmed.ncbi.nlm.nih.gov/8602629
Autor:
P J, Hollen, R J, Gralla, M G, Kris, C, Cox, C P, Belani, S M, Grunberg, J, Crawford, J A, Neidhart
Publikováno v:
Cancer. 73(8)
This study continued the development and psychometric testing of the Lung Cancer Symptom Scale (LCSS), a disease- and site-specific instrument primarily measuring the physical and functional dimensions of quality of life for individuals with lung can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8bbb3806b5c90bd4d7ebc223605a019a
https://pubmed.ncbi.nlm.nih.gov/8156514
https://pubmed.ncbi.nlm.nih.gov/8156514
Autor:
Jeffrey D. Neidhart, Edward B. Garon, Nashat Y. Gabrail, S. P. Lu, J. A. Neidhart, Moacyr Ribeiro de Oliveira, J. Balkissoon, Fairooz F. Kabbinavar
Publikováno v:
Journal of Clinical Oncology. 29:7559-7559
7559 Background: Inhibition of angiogenesis has clinical benefits in NSCLC. Depriving tumors of blood flow by adding bevacizumab (B) to other vasculature-directed agents has been hampered by toxici...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3aa1e5b2ed2c60931b0be04ab2105cb8
https://doi.org/10.1200/jco.2011.29.15_suppl.7559
https://doi.org/10.1200/jco.2011.29.15_suppl.7559
Autor:
J A, Neidhart
Publikováno v:
Cancer. 72
The introduction of hematopoietic cytokines into the clinic has been rapid with three currently approved by the Food and Drug Administration and perhaps a dozen more in clinical trials. Combinations of cytokines have been relatively unexplored in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8722b9e0315aaf66a768a60b38b4cc17
https://pubmed.ncbi.nlm.nih.gov/8242571
https://pubmed.ncbi.nlm.nih.gov/8242571
Publikováno v:
Biotechnology therapeutics. 4(3-4)
Substantial increases in dose-intensity of chemotherapy yield a severalfold increase in complete remission rates and durable responses in several types of malignant disease. Hematopoietic colony-stimulating factors decrease the duration of the result
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::342b8f305c156208bd3b82303c260744
https://pubmed.ncbi.nlm.nih.gov/8292969
https://pubmed.ncbi.nlm.nih.gov/8292969
Autor:
Nashat Y. Gabrail, Jeffrey D. Neidhart, Edward B. Garon, J. Balkissoon, Fairooz F. Kabbinavar, S. P. Lu, Moacyr Ribeiro de Oliveira, J. A. Neidhart
Publikováno v:
Journal of Clinical Oncology. 28:7587-7587
7587 Background: CA4P is a small-molecule tumor vascular disrupting agent (VDA) that has shown additive effects in combination with chemotherapy and antiangiogenic therapy. This phase II study eval...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f935ecba83ea570e32ecb5e63261d8d
https://doi.org/10.1200/jco.2010.28.15_suppl.7587
https://doi.org/10.1200/jco.2010.28.15_suppl.7587
Autor:
D A, Clark, J A, Neidhart
Publikováno v:
Seminars in hematology. 29(4 Suppl 3)
GM-CSF decreases the hematopoietic toxicity of both nonablative and marrow ablative intensive chemotherapy regimens. Data are limited at this time, particularly in regard to optimal schedules and GM-CSF dosing regimens with particular chemotherapy pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bb569b4818183454b00048e2a1849a31
https://pubmed.ncbi.nlm.nih.gov/1492231
https://pubmed.ncbi.nlm.nih.gov/1492231
Autor:
J A, Neidhart
Publikováno v:
Cancer. 70
Three hematopoietic colony-stimulating factors (CSF) are currently approved for clinical use and several more are being used in clinical trials. These factors have impressive quantitative and/or functional effects on their respective target cell line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a36632ed62f6939a97055df7e776efcc
https://pubmed.ncbi.nlm.nih.gov/1379115
https://pubmed.ncbi.nlm.nih.gov/1379115
Autor:
J. A. Neidhart
Publikováno v:
High-Risk Breast Cancer ISBN: 9783642747304
Anthracyclines have now been used for treatment of breast cancer for almost two decades. The goal of prolonged life of good quality remains elusive for most women with cancer of the breast although our ability to palliate has improved greatly. We hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c68ae619c9ad7dc6b7848aa9f42507d
https://doi.org/10.1007/978-3-642-74728-1_17
https://doi.org/10.1007/978-3-642-74728-1_17
